Anika Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Anika Therapeutics, Inc. (ANIK) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $11.00 thousand as of 2025-06-30, per its 10-Q filed 2025-07-30.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2025-07-30
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $11.00K.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $281.00K.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $252.00K.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $672.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2025-06-30 | $11.00K 10-Q · filed 2025-07-30 |
| 2025-03-31 | $281.00K 10-Q · filed 2025-05-09 |
| 2024-09-30 | $252.00K 10-Q · filed 2024-11-04 |
| 2024-06-30 | $672.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.01M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |